Home
TNFA
TNFA News

Latest TNF PHARMACEUTICALS INC EFFEC (TNFA) News on July 1, 2025

TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

Business Wire

6 days ago

TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists

Business Wire

2 months ago

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

Business Wire

2 months ago

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025

Business Wire

2 months ago

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025

TNF Pharmaceuticals presents isomyosamine data

TipRanks

3 months ago

TNF Pharmaceuticals presents isomyosamine data

TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia

Business Wire

3 months ago

TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia

TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

Business Wire

4 months ago

TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

Business Wire

4 months ago

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

Business Wire

5 months ago

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

Business Wire

6 months ago

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

Business Wire

6 months ago

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

Business Wire

7 months ago

TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market

Business Wire

9 months ago

TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

Business Wire

10 months ago

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

Share on Social Networks: